NCT00260923

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg, 150 mg and 300 mg to Placebo in Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 641 (actual)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	aliskiren

Timeline

• Start date: 2005-11-01
• Primary completion: 2006-11-01
• Completion: 2006-11-01
• First posted: 2005-12-02
• Last updated: 2011-11-08

Locations

2 sites across 2 countries: United States, Germany